Skip to main content
. Author manuscript; available in PMC: 2023 Apr 12.
Published in final edited form as: Ann Allergy Asthma Immunol. 2022 Jun 21;129(3):319–326.e3. doi: 10.1016/j.anai.2022.06.017

Table 1.

Demographics

n = 120 Controlled (n = 33) Uncontrolled (n = 87) P
Age (y), median (Q1, Q3) 11.05 (6.1, 15.0) 11.15 (7.6, 15.0) .92
Male sex, n (%) 20 (60.6%) 52 (59.8%) >.99
Race and ethnicity, n (%) .21
 White 5 (15.1%) 18 (20.7%)
 Black 27 (81.8%) 71 (81.6%)
 Hispanic 1 (3.0%) 1 (1.1%)
 Native American 0 (0%) 2 (2.3%)
Residence type, n (%) .90
 Apartment 7 (21.2%) 18 (20.7%)
 House 23 (68%) 23 (70%)
 Townhouse or duplex 1 (3.0%) 4 (4.6%)
 Trailer house 1 (3.0%) 5 (5.7%)
 No answer 1 (3.0%) 1 (1.1%)
 Carpet in house, n (%) 19 (57.6%) 61 (70.1%) .19
 Pets, n (%) 10 (30.3%) 35 (40.2%) .31
Heating and air, n (%) .31
 Central 21 (63.6%) 69 (79.3%)
 Window units 0 (0%) 2 (2.3%)
 Electric base board 6 (18.2%) 7 (8.0%)
 Heat pump 2 (6.1%) 3 (3.4%)
 Other 4 (12.1%) 5 (5.7%)
 No answer 0 (0%) 1 (1.1%)
Inhaled corticosteroids, n (%) 18 (54.5%) 57 (65.5%) .26
ACT, mean (SD) 21.54 (1.75) 14.42 (3.37)
FEV1, mean (SD)
 (n = 27)
 (5 Controlled)
 (22 Uncontrolled)
2.54 (0.33) 1.91 (0.73) .01
Positive viral tests, n (%) 18 (58.1%) 65 (75.6%) .06
Positive RV tests, n (%) 10 (32.3%) 36 (45.0%) .22
RV co-infections, n (%) 4 (12.9%) 14 (17.9%) .72

Abbreviations: ACT, asthma control test; FEV1, forced expiratory volume in 1 second; RV, rhinovirus.